Arbutus says FDA grants Fast Track designation for hepatitis B drug imdusiran

• Arbutus Biopharma disclosed FDA Fast Track designation for imdusiran in chronic hepatitis B.
• Trial results were already presented, showing some patients reached a functional cure or stopped medication.
• Fast Track status could speed development, supporting earlier FDA interaction.
• Designation also opens path to expedited review options for a future application if criteria are met.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-002458), on April 15, 2026, and is solely responsible for the information contained therein.